| Recruiting | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease ( Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 3 | 2026-03-27 |
| Recruiting | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | 2026-03-10 |
| Recruiting | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2026-02-13 |
| Recruiting | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advan Advanced Solid Tumor | Phase 1 | 2025-10-10 |
| Completed | A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial i Hypogonadism | Phase 1 | 2025-07-21 |
| Withdrawn | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) Advanced Solid Tumors | Phase 1 | 2025-05-14 |
| Recruiting | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | 2025-01-29 |
| Recruiting | Anti-GD2 ADC M3554 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-11-08 |
| Active Not Recruiting | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC Ovarian Cancer | Phase 2 | 2024-10-30 |
| Terminated | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Ca Advanced Solid Tumor | Phase 1 | 2024-10-08 |
| Withdrawn | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Urothelial Carcinoma | Phase 2 | 2024-08-16 |
| Active Not Recruiting | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) Advanced Solid Tumor | Phase 1 | 2024-08-07 |
| Terminated | Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (Hyperl Head and Neck Cancer | Phase 1 | 2024-01-18 |
| Active Not Recruiting | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-09-13 |
| Terminated | Study of M5049 in DM and PM Participants (NEPTUNIA) Dermatomyositis, Polymyositis | Phase 2 | 2023-01-19 |
| Terminated | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Parti Head and Neck Cancer | Phase 3 | 2022-10-06 |
| Recruiting | Met Non Small Cell Cancer Registry (MOMENT) Cancer | — | 2022-10-04 |
| Active Not Recruiting | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metas Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | 2022-08-17 |
| Recruiting | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) Colorectal Cancer | Phase 1 | 2022-08-04 |
| Active Not Recruiting | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor ( Metastatic or Locally Advanced Unresectable Solid Tumors | Phase 1 | 2022-06-07 |
| Completed | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) Systemic Lupus Erythematosus | Phase 2 | 2022-03-31 |
| Terminated | First in Human Study of M1069 in Advanced Solid Tumors Metastatic or Locally Advanced Unresectable Solid Tumors | Phase 1 | 2022-03-02 |
| Active Not Recruiting | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors Central Nervous System Tumors | Phase 1 | 2021-12-03 |
| Completed | Bintrafusp Alfa Program Rollover Study Lung Cancer, Cancer | Phase 3 | 2021-12-01 |
| Terminated | Next-Gen MS: Feed-forward PRO Data for MS Research Multiple Sclerosis (MS) | — | 2021-11-02 |
| Completed | First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) Advanced Solid Tumors | Phase 1 | 2021-05-24 |
| Completed | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Small-cell Lung Cancer | Phase 2 | 2021-03-29 |
| Completed | The MS-LINK™ Outcomes Study Multiple Sclerosis | — | 2021-03-24 |
| Terminated | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Color Colorectal Neoplasms | Phase 2 | 2021-01-28 |
| Completed | M1231 in Participants With Solid Tumors Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer | Phase 1 | 2021-01-13 |
| Withdrawn | Study of M4344 in Combination With Niraparib Advanced Solid Tumor, Breast Cancer | Phase 1 / Phase 2 | 2020-12-01 |
| Completed | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) Cervical Cancer | Phase 1 | 2020-10-19 |
| Terminated | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer Triple Negative Breast Neoplasms | Phase 2 | 2020-10-12 |
| Terminated | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Squamous Cell Carcinoma of the Head and Neck | Phase 3 | 2020-08-07 |
| Completed | Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE) Coronavirus Disease 2019 | Phase 2 | 2020-07-29 |
| Completed | First in Human Study of M6223 Metastatic Solid Tumors | Phase 1 | 2020-07-10 |
| Completed | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Uterine Cervical Neoplasms | Phase 2 | 2020-03-30 |
| Active Not Recruiting | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Soli Metastatic or Locally Advanced Unresectable Solid Tumors | Phase 1 | 2019-12-20 |
| Terminated | First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dex Multiple Myeloma | Phase 1 | 2019-09-26 |
| Terminated | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | Phase 2 / Phase 3 | 2019-09-20 |
| Active Not Recruiting | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Non-small Cell Lung Cancer | Phase 2 | 2019-09-19 |
| Terminated | Study of Evobrutinib in Participants With RMS Relapsing-remitting Multiple Sclerosis | Phase 3 | 2019-09-10 |
| Terminated | Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) Relapsing-remitting Multiple Sclerosis | Phase 3 | 2019-08-26 |
| Completed | Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) Multiple Sclerosis (MS) | Phase 4 | 2019-08-15 |
| Completed | A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Multiple Sclerosis | — | 2019-07-22 |
| Completed | A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS) Multiple Sclerosis | — | 2019-05-21 |
| Terminated | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer | Phase 2 | 2019-04-16 |
| Completed | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2019-04-02 |
| Completed | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | 2019-03-26 |
| Active Not Recruiting | Avelumab Program Rollover Study Solid Tumors | Phase 3 | 2019-03-22 |
| Completed | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer Locally Advanced Rectal Cancer | Phase 1 / Phase 2 | 2019-03-20 |
| Completed | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer Ovarian Cancer | Phase 1 | 2019-03-04 |
| Completed | Study of Avelumab-M3814 Combinations Oncology, Solid Tumors | Phase 1 | 2018-11-27 |
| Completed | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L Non-small Cell Lung Cancer | Phase 3 | 2018-10-01 |
| Completed | Tepotinib Hepatic Impairment Trial Hepatic Impairment | Phase 1 | 2018-06-13 |
| Terminated | Phase I/II Study of Avelumab in Pediatric Cancer Participants Refractory or Relapsed Solid Tumors, Lymphoma | Phase 1 | 2018-03-07 |
| Terminated | First-in-Human Study of MS201408-0005A as Single Agent and in Combinations Metastatic or Locally Advanced Unresectable Solid Tumors | Phase 1 | 2017-10-03 |
| Completed | Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2017-09-18 |
| Terminated | M3541 in Combination With Radiotherapy in Solid Tumors Solid Tumors | Phase 1 | 2017-09-06 |
| Completed | Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes Relapsing-Remitting Multiple Sclerosis | — | 2017-08-23 |
| Terminated | M8891 First in Human in Solid Tumors Advanced Solid Tumors, Metastatic Renal Cell Carcinoma | Phase 1 | 2017-08-08 |
| Terminated | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED Small Cell Lung Cancer | Phase 1 | 2017-05-25 |
| Terminated | A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis Relapsing-remitting Multiple Sclerosis | Phase 2 | 2017-03-07 |
| Terminated | Efficacy and Safety of Atacicept in IgA Nephropathy IgA Nephropathy | Phase 2 | 2017-01-31 |
| Terminated | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination Wi Advanced Solid Tumors | Phase 1 | 2017-01-31 |
| Terminated | A Phase II Study of M2951 in SLE Systemic Lupus Erythematosus | Phase 2 | 2017-01-04 |
| Active Not Recruiting | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV | Phase 2 | 2016-09-13 |
| Completed | Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2016-07-31 |
| Terminated | Abituzumab in SSc-ILD Systemic Sclerosis-associated Interstitial Lung Disease | Phase 2 | 2016-05-31 |
| Completed | First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Com Advanced Solid Tumor | Phase 1 | 2016-02-29 |
| Completed | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | Phase 3 | 2015-12-28 |
| Completed | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Phase 3 | 2015-12-24 |
| Completed | MSC2364447C Phase 1b in Systemic Lupus Erythematosus Lupus Erythematosus, Systemic | Phase 1 | 2015-11-30 |
| Completed | Avelumab in First-line NSCLC (JAVELIN Lung 100) First Line Non-Small Cell Lung Cancer | Phase 3 | 2015-10-29 |
| Completed | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Advanced Solid Tumors | Phase 1 | 2015-09-15 |
| Completed | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Solid Tumors | Phase 1 | 2015-08-31 |
| Completed | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Carcinoma, Non-Small-Cell Lung | Phase 3 | 2015-03-24 |
| Completed | First in Human Study of M4344 in Participants With Advanced Solid Tumors Solid Tumor, Advanced Solid Tumor | Phase 1 | 2015-01-26 |
| Completed | Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) Carcinoma, Merkel Cell | Phase 2 | 2014-07-03 |
| Completed | A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Oste Osteoarthritis, Knee | Phase 2 | 2013-07-29 |
| Completed | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Solid Tumors | Phase 1 | 2013-01-31 |
| Completed | M6620 First in Human Study Advanced Solid Tumor | Phase 1 | 2012-12-10 |
| Completed | Oral Cladribine in Early Multiple Sclerosis (MS) Multiple Sclerosis | Phase 3 | 2008-12-31 |
| Completed | CLARITY Extension Study Relapsing-Remitting Multiple Sclerosis | Phase 3 | 2008-02-29 |
| Completed | A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects Multiple Sclerosis | Phase 2 | 2006-11-30 |